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Abstract: There is a growing body of evidence documenting probiotic bacteria to have a beneficial
effect to the host through their ability to modulate the mucosal immune system. Many probiotic
bacteria can be considered to act as either immune activators or immune suppressors, which have
appreciable influence on homeostasis, inflammatory- and suppressive-immunopathology. What is
becoming apparent is the ability of these probiotics to modulate innate immune responses via direct
or indirect effects on the signaling pathways that drive these activatory or suppressive/tolerogenic
mechanisms. This review will focus on the immunomodulatory role of probiotics on signaling
pathways in innate immune cells: from positive to negative regulation associated with innate immune
cells driving gut mucosal functionality. Research investigations have shown probiotics to modulate
innate functionality in many ways including, receptor antagonism, receptor expression, binding to
and expression of adaptor proteins, expression of negative regulatory signal molecules, induction of
micro-RNAs, endotoxin tolerisation and finally, the secretion of immunomodulatory proteins, lipids
and metabolites. The detailed understanding of the immunomodulatory signaling effects of probiotic
strains will facilitate strain-specific selective manipulation of innate cell signal mechanisms in the
modulation of mucosal adjuvanticity, immune deviation and tolerisation in both healthy subjects and
patients with inflammatory and suppressive pathology.
Keywords: probiotics; innate; epithelial cells; dendritic cells; neutrophils; macrophages; signaling;
immunomodulation; cytokines; inflammation
1. Introduction
Probiotics have been shown to both augment/modulate homeostatic immune defences and
to ameliorate specific infectious, inflammatory and allergic diseases by modulating gut function.
Probiotics are described as “Live microorganisms, which, when consumed in adequate amounts,
confer a health benefit on the host” by the Food and Agricultural Organization of the United Nations
and the World Health Organization [1]. Although probiotics can be beneficial in specific human
health and clinical applications, the mechanisms used to modulate immune function and mucosal
integrity are poorly understood. In general, there is an ever-increasing body of evidence that describes
probiotic bacteria to modulate mucosal immunity at the level of barrier effects, pathogen sensing,
innate and adaptive responses. The gut mucosa, the front line barrier to food antigens, pathogens and
commensal organisms, is predominated by cells of the innate immune system such as macrophages
(MΦs) and dendritic cells (DCs) which, through their ability to produce immune signaling cytokines
and act as antigen presenting cells (APCs), can dictate overall immune function as activatory or
regulatory. In order to understand how probiotics exert their beneficial effects, the cellular and
molecular mechanisms involved in the modulation of innate signaling pathways needs to be clarified.
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This will be critical for the appropriate selection of probiotic strains for pharmacobiotic strategies used
in prophylaxis and the direct treatment of specific clinical conditions.
Probiotics are typically, although not necessarily commensal bacteria. They are generally lactic
acid bacteria (LAB), most commonly lactobacilli and bifidobacteria species, although lactococcus,
streptococcus and enterococcus species, as well as some non-pathogenic Escherichia coli strains are
also known probiotics [2]. These probiotics have numerous effects on the gastrointestinal tract
(GIT) and the gut-associated lymphoid tissue (GALT) where they modulate intestinal function
and immune responses via augmentation of activation (adjuvanticity), and regulation/tolerisation
(reviewed in [3]). These effects include the competitive exclusion of pathogens at the intestinal barrier,
modulation of dendritic cell (DC) function, influencing T cell polarization and suppression of intestinal
inflammation. This results as a consequence of the down-regulation of pro-inflammatory cytokine
release from immune cells by the activation, up-regulation of endogenous suppressors, inhibition and
cross-regulation of signaling pathways, including nuclear factor-kappa B (NF-κB), mitogen activated
protein kinases (MAPK), Janus kinase/Signal transducers and activators of transcription (JAK/STATs)
and phosphatidyl inositol 3-kinase (PI3K) [4].
The subtleties of innate immune responses directed by probiotic bacteria are likely to be portrayed
in the complexities of signaling pathways activated and the cross-talk between them. Thus, the aim of
this review is to explore the many innate immune reception events and signaling pathways modulated
by probiotics, and how these affect intestinal function and innate immune responses. The ways in
which probiotics are recognised by innate immune receptors will also be explored, with a particular
emphasis on pathogen sensing, barrier integrity, anti-microbial and innate immune responses driven
by intestinal epithelial cells (IECs) and the immune cells underneath this barrier such as the DCs, MΦs,
neutrophils (NΦs) and natural killer cells (NKs).
2. Probiotic Modulation of Intestinal Epithelial Cells
In the context of gut homeostasis, there is a fine balance between epithelial cell proliferation,
differentiation and apoptosis, allowing this dynamic cellular barrier to continually replace itself,
protect from infectious pathogenic agents and to die off prior to cellular transformation resulting
from long-term exposure to carcinogenic agents present in intestinal/digesta-associated water.
Intestinal epithelial cells (IECs) represent the physical barrier that maintains the segregation between
luminal microbes, digesta and the mucosal immune system [5]. Probiotics and commensals can
modulate IEC function in a variety of ways, including indirect effects on microbial biofilms [6]
and direct effects on IECs via enhancement of barrier function by enhancing tight junctions
and mucin production [7]; induction of antimicrobial peptides (AMPs) and heat shock protein
production [8,9]; modulation of pro-inflammatory and immunoregulatory cytokines and interference
with pathogenesis [10,11]. The functions of the intact epithelial barrier rely on intracellular signaling
cascades, on which probiotics exert their effects. These effects are being elucidated by an increasing
number of both in vitro and in vivo studies (refer to both Table 1 and Figure 1).
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Figure  1. Probiotic modulation of  intestinal  epithelial  cell  signaling pathways Probiotic‐mediated 
modulation of epithelial cell responses via activation or suppression of distinct signaling pathways is 
species‐dependent.  Mechanisms  of  modulation  are  presented  above  for  a  range  of  species  of 
Bifidobacteria, Lactobacilli, Streptococcus, VSL#3 mixture and the yeast S. cerevisiae, indicated in the 
luminal space above the square epithelial cells; additionally, LGG, L. rhamnosus strain GG; LGGp40, 
LGG secreted p40 protein; LP, L. plantarum; Lca, L. casei. Mechanisms are indicated by numbers 1–8 
in orange boxes: 1. Anti‐apoptotic, 2. Antimicrobial defence, 3. Reinforcement of tight junction (TJ), 4. 
Reinforcement of TJ (gene expression & translocation to TJ), 5. Pathogen sensing, 6. Protection against 
TJ damage, 7. & 8. Suppression of inflammatory cytokines. Arrowed lines are activatory, blunted lines 
are  suppressive/inbibitory.  Light  blue  boxes  between  epithelial  cells  are  representative  of  tight 
junctions. Dark blue boxes represent PRRs, predominantly TLR2. Dark green box on apical surface is 
an, as yet unidentified  receptor  for LGGp40. EGFR, Epithelial growth  factor  receptor; Src,  serine‐
threonine kinase; ZO‐1, zonula occludens‐1; AMPs, antimicrobial peptides; TNFα, tumour necrosis 
factor‐alpha; PRR, pattern recognition receptors; PKC, protein kinase C; PI3K, phosphatidyl inositol 
3‐kinase. 
2.1. Modulation of Barrier Function 
Epithelial growth factor receptor (EGFR) is expressed by IECs and mediates various biological 
functions, including cellular proliferation, differentiation and cell survival [12]. EGFR is activated by 
its soluble  ligand EGF, which triggers the formation of homo‐ and hetero‐dimers with other ErbB 
receptor tyrosine kinases, activating the auto‐phosphorylation of several cytoplasmic proteins [13]. 
The  tyrosine‐phosphorylated  EGFR  indirectly  recruits  several  adaptor  proteins,  which  activate 
various downstream signaling pathways such as protein kinase C (PKC), PI3K and MAPK. These 
pathways induce the production of tight junction proteins and enhance epithelial barrier integrity. 
Probiotic strains have been described to regulate some of these signaling cascades, augmenting tight 
junction integrity, survival of IECs and modulation of mucosal barrier immunity [10]. 
Enhancement  of  Tight  junction  strength:  Epithelial  barrier  integrity  is  determined  by  the 
strength of tight junctions (TJ) [12]. These tight junctions are composed of transmembrane proteins 
[14], whose  assembly  is dependent on  the  activation of MAPK  signaling pathways. Some of  the 
proteins involved in the formation of tight junctions are zonula occludens (ZO)‐1, a scaffold protein; 
occludin, a transmembrane protein and Claudin‐1, an integral membrane protein localized at tight 
junctions  [15]. Probiotics can enhance barrier  function by preventing  the destruction of  intestinal 
paracellular permeability. It has been shown that Lactobacillus rhamnosus GG (LGG) up‐regulates the 
expression of ZO‐1, Claudin‐1 and Occludin in the human colon‐derived intestinal epithelial cell line, 
Caco‐2 [16]. Moreover,  the mechanisms by which probiotics control  intestinal barrier  function are 
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ZO-1, Claudin-1 and Occludin in the human colon-derived intestinal epithelial cell line, Caco-2 [16].
Moreover, the mechanisms by which probiotics control intestinal barrier function are beginning
to be clarified. An investigation of the effects of Lactobacillus plantarum on Caco-2 intestinal cells
induced TLR2 signaling-mediated translocation of ZO-1 to the TJ region between epithelial cells [17].
Pre-treatment of Caco-2 monolayers with L. plantarum or the Toll-like receptor-2 (TLR2) agonist, Pam3-
Cys-SK4 (P3CSK), significantly attenuated the effects of phorbol ester-induced dislocation of ZO-1
and occludin and the associated increase in epithelial permeability. The phorbol ester, PMA, is an
analogue of the protein kinase C (PKC)-activating diacyl glycerol (DAG); taken together with the
observations above, it is suggestive of a reciprocle relationship between MAPK and PKC signaling.
The understanding of this relationship will only be clarified by more detailed studies investigating
the relative utilisation of MAPK and PKC isoforms. These effects however, may be strain- and
dose-specific. It has also been demonstrated that expression of TLR2 mRNA is up-regulated in
IPEC-J2 cells (neonatal porcine mid-jejunum derived) when pre-treated with LGG, suggesting that
TLR2 recognition of gram-positive probiotic bacteria plays a significant role in strengthening barrier
integrity [18]. Furthermore, pre-treatment with LGG suppressed the F4+ ETEC (Enterotoxigenic
Escherichia coli K88)-induced increase in the pro-inflammatory cytokine, tumour necrosis factor-alpha
(TNFα). These results identify TLR2 stimulation by probiotic bacteria as a regulator of epithelial
integrity and may have implications for the understanding of downstream probiotic mechanisms and
the subsequent control of intestinal homeostasis (refer to Figure 1).
The downstream effects of TLR activation include two very important signaling cascades,
involving the MAPK and NFκB pathways. It was observed that probiotics can modulate intestinal
epithelial permeability via up-regulation and activation of MAPK pathways (refer to Table 1).
The MAPKs consist of numerous serine-threonine protein kinases of which extracellular signal-related
kinases (ERK), c-Jun amino-terminal kinases (JNK), and p38 are the primary members [19]. Activation
of ERK and JNK results in activation and nuclear translocation of the transcription factor, AP-1,
and the subsequent transcription of pro-inflammatory genes including TNFα. A study carried out
by Dai et al. (2012) [20] used the VSL#3 probiotic mixture (consisting of 8 different Gram positive
bacteria: B. longum, B. infantis, B. breve, L. acidophilus, L. casei, L. delbrueckii ssp. bulgaricus, L. plantarum
and Streptococcus salivarius ssp. thermophilus) to characterise the in vivo effects on a murine acute
dextran sodium sulphate DSS-induced colitis model, and paralleled in vitro TNFα-cultured human
HT-29 (human colon adenocarcinoma epithelial) cell effects on tight junction proteins (occludin, ZO-1)
and MAPK signaling. It was observed that VSL#3 ameliorated the disease in vivo, due to increased
expression of tight junction proteins (occludin and ZO-1) which were dependent on the activation of
both ERK and p38 MAPKs. Moreover, the in vitro effects of VSL#3 on the tight junction proteins were
abbrogated by SB203580 and U0126, p38 and ERK inhibitors, respectively. These studies are suggestive
of probiotic-dependent mechanisms are involved in the regulation of epithelial integrity and that this
regulation results from the contribution of both ERK and p38 MAPK signaling pathways to intestinal
homeostasis. Of particular interest to this study was the inclusion of investigation focussed on JNK,
however the probiotic-mediated barrier repair through the induction of TJ proteins was found to be
independent of JNK signaling. Coupled with the understanding of JNK signaling being associated with
stress responses; these studies would suggest that there is differential activation of MAPK pathways in
reparative versus stress/inflammatory responses in epithelial barriers.
Preventing apoptosis: As indicated earlier, the balance between cell proliferation and cell death
represents a fine line between homeostasis, the ability to mount efficient defences to pathogens and
mucosal pathology. In addition to tight junction enhancement, probiotics have been shown to confer
protection against many cellular stresses, which include oxidative stress-mediated apoptosis [21].
The LGG strain ATCC53103 was shown to secrete p40 and p75 soluble proteins in fermented
milk, where the p40 soluble protein has been shown to ameliorate cytokine-induced apoptosis in
YAMC (young adult mouse colon) cells by the transactivation of EGFR and subsequent activation
of the PI3K-downstream substrate, Akt/PKB [21]. It has since been found that p40 stimulates Src
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(serine-threonine kinase) activation in IECs, which induces the release of EGF via the activation of
matrix metalloproteinases (MMPs). Hence, p40 activation of EGFR is src-dependent, as evidenced by
Src-inhibition blocking p40-mediated activation of EGFR [22]. This suggests that Src may serve as an
upstream mechanism for p40 transactivation of EGFR and the subsequent activation of the downstream
signal effector, Akt/PKB in intestinal epithelial cells, which prevents apoptosis. Moreover, in a similar
study, LGG also attenuated H2O2-induced disruption of the tight junction complex in IECs [23].
These studies together demonstrate how LGG protein products can enhance membrane barrier integrity
and protective responses by activation of the anti-apoptotic PKB/Akt in a PI3K-dependent manner to
protect IECs from cytokine-induced apoptosis. The ability of probiotics to regulate IEC apoptosis may
be a useful strategy for the prevention of reduced membrane integrity caused by enteric infections
and inflammatory disorders. The soluble proteins produced by LGG ATCC53103 have been shown to
successfully prevent colitis in vivo in a DSS induced mouse model [24]. Just whether this prophylactic
protective response can be translated to a therapeutic use in established disease, remains to be clarified
(refer to Table 1).
Table 1. Probiotic modulation of signaling pathways in intestinal epithelial cells.
Probiotic Species
(Soluble Product)
Probiotic–Induced
Effector Response Cells/Cell Line Signaling Pathway Reference
Bifidobacteria breve M-16V
Bifidobacteria longum BB536
Increase IL-8, MCP-1 and
IL-6 levels PIE cells NFκB via activation of A20 [25]
Bifidobacteria lactis KCTC 5727 Suppress NFκB-bindingactivity & IκB degradation HT-29 cells NFκB [26]
Lactobacillus amylovorus
DSM 16698T
Decrease ETEC-induced IL-8
& IL-1β production
Caco-2/TC7 cells (higher
transport activity).
TLR4 signaling via
activation of Tollip and
IRAK-M
[27]
Lactobacillus casei OLL2768 Decrease IL-6, IL-8, IL-1α andMCP-1 BIE cells NFκB and p38 MAPK [28]
Lactobacillus rhamnosus GG Increased expression ofIL-10R2
Ex vivo C57 BL/6J mice
Immature colon samples
Phospho-STAT3, increased
expression of SOCS-3 [29]
Lactobacillus rhamnosus GG TLR2 up-regulation IPEC-J2 TLR signaling [18]
Lactobacillus rhamnosus GG
(LGG)
Reduce NFκB activation
via ROS
FHs74Int cells (human
foetal) NFκB [30]
Lactobacillus rhamnosus GG p40
and p75 proteins Enhance tight junction YAMC EGFR/Akt [23,24,31]
Lactobacillus rhamnosus GG p40
protein (LGGp40)
Decrease cytokine-induced
apoptosis YAMC EGFR/Akt via Src [22]
Lactobacillus jensenii TL2937 Activate negative regulatorsA20, Bcl-3 and MKP-1 PIE cells
TLR4-dependent NFκB
and MAPK [32]
Lactobacillus plantarum (LP)
WCFS1
Increased tight
junction proteins Caco-2 cells TLR2 signaling [17]
Lactobacillus reuteri DSM 17938 Inhibit IκB phosphorylation Ex vivo rat model NFκB [33]
Saccharomyces cerevisiae (Sc)
CNCM I-3856
Decrease IL-6 and
IL-8 expression IPEC-1
Decrease of ERK1/2 and
p38 phosphorylation [34]
Streptococcus salivarius K12 Inhibit NFκB activity HT-29 NFκB [35]
VSL#3 Increased tightjunction proteins HT-29 cells
Phosphorylation of ERK
and p38 MAPKs [20]
VSL#3 Induction of heat shockproteins (hsp) Colonic IECs
Suppression of NFκB via
inhibition of proteosome [36]
Probiotics differentially modulate epithelial cell responses via activation or suppression of distinct signaling
pathways in a strain-dependent manner. Observations presented include a range of strains of bifidobacteria,
lactobacilli, streptococcus, VSL#3 mixture and the yeast, S. cerevisiae (Sc). Epithelial cell models include human
(Caco-2, Caco-2/TC7 (late passage clone), HT-29, FHs74Int), murine (YAMC), porcine (porcine intestinal epithelium
PIE, intestinal porcine epithelial cells, IPEC), and bovine (BIE) cells. Endogenous negative regulators of TLR signaling
(IRAK-M, Interleukin receptor-associated kinase-M; Tollip, Toll interacting protein; A20, TNF-inducible zinc finger
protein A20; Bcl-3, proto-oncogene 3 of B cell chronic lymphocytic leukaemia; MKP-1, mitogen-activated protein
kinase phosphatase-1). Cytokines indicated are Interleukin (IL)-1α, -1β, -6, -8, -10, IL-10R2, IL-10 Receptor subunit 2
and MCP-1, monocyte chemoattractant protein -1. ROS, reactive oxygen species. NFκB, Nuclear factor kappa B;
ETEC, Enterotoxigenic Escherichia coli; TLR, Toll-Like Receptor; MAPK, mitogen activated protein kinases; SOCS,
suppressor of cytokine signaling; EGFR, epithelial growth factor receptor; ERK, extracellular signal-related kinases.
2.2. Modulation of Mucosal Immunity
There is increasing research in the use of probiotics for decreasing pathogen-induced
pro-inflammatory responses and ameliorating GI diseases. The results from this research may be
critical for the evaluation of the mechanisms of action utilised by different probiotic strains and how
they can prevent the inflammatory effects of infectious agents (refer to both Table 1 and Figure 1).
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Pathogens are recognised by the innate immune systems pattern recognition receptors (PRR).
These receptors bind pathogen-associated molecular patterns (PAMPs), which are common conserved
structures shared by the vast majority of pathogens. PRRs include Toll-like receptors (TLR), NOD-like
receptors (NLR), Rig-1-like receptors (RLRs) and C-type lectins (CLRs). TLRs are membrane bound
and provide pathogen surveillance, which upon ligand binding, activate NFκB signaling, leading to
the production of pro-inflammatory cytokines, chemokines and antimicrobial peptides [37]. NLRs are
cytoplasmic receptors that also provide host defense via the activation of NFκB signaling [38]. To date,
the human TLR family consists of 10 members. TLR1, 2, 4, 5, 6, and 10 are cell surface membrane
bound and primarily respond to bacterial PAMPs. TLR3, 7 8 and 9 are found on intracellular
components, where they respond primarily to nucleic acid-based PAMPs from viruses or bacteria [39].
Interaction of TLRs, except TLR3, with its ligand, leads to the recruitment of intracellular adaptor
proteins, which contain a toll-IL-1 receptor (TIR) domain (reviewed in [38]). These include MyD88
(myeloid differentiation primary response gene 88), TIRAP/MAL (TIR domain containing adaptor
protein) and TRIF (toll receptor—IL-1 receptor factor). The adaptor proteins interact with the
receptor through TIR-TIR binding which results in the recruitment of IL receptor-associated kinases
(IRAK-1,2 & -4) and TNF receptor-associated factor 6 (TRAF6). This leads to the activation of the
mitogen-activated protein kinases (MAPK) (ERK, JNK and p38), and subsequently transcription factors
NFκB and AP-1. Activation of these transcription factors induces production of pro-inflammatory
(IL1β, IL-6, IL-8, TNFα) and anti-inflammatory (IL-10) cytokines and anti-viral type 1 interferons
(IFNα, IFNβ) [40].
The NFκB pathway is an important signaling cascade for the activation of various immune
responses. NFκB is composed of several protein subunits, which regulate the transcription of effector
genes including the pro-inflammatory cytokine TNFα and the neutrophil chemokine, IL-8 [41].
During non-stimulatory conditions, NFκB is inactive in the cytoplasm, bound to the inhibitor
molecule IκB. Upon activation, IκB is phosphorylated by IKK, which targets it for ubiquitination.
NFκB is subsequently freed from IκB, which upon unmasking of the nuclear localization sequence
(NLS), the NFκB p65/p50 heterodimer is able to migrate into the nucleus where it functions as a
transcription factor at target promoter regions. Among the many upstream signaling proteins involved
in NFκB activation is TLR4, which plays a critical role in many intestinal inflammatory diseases [42].
TLR4 recognises LPS from Gram-negative bacteria. Many signaling molecules in the TLR4/NFκB
pathway present opportunities for probiotic modulation of activation of pro-inflammatory responses
(refer to Figure 1, below). Increasing research efforts have been focused on the down-regulation
of the inflammatory response to Enterotoxigenic Escherichia coli (ETEC) via modulation of this
TLR4/NFκB pathway, thus probiotic bacterial strains would appear to modulate LPS/Gram-negative
bacteria-induced inflammatory responses.
Negative regulation of TLR4 signaling: TLR4 is expressed on epithelial and immune cells and
responds to PAMPs on Gram-negative bacteria, most commonly LPS. The intestinal immune system
therefore, must constantly maintain a tightly controlled balance between activation and inhibition of
TLRs to avoid detrimental unintended stimulation by the microflora and inappropriate inflammatory
responses. In order to prevent inappropriate responses to commensal and pathogenic bacteria, various
negative regulators exist to attenuate TLR signaling [43] (refer to Figure 2). Negative regulators include
membrane bound suppressors such as single immunoglobulin interleukin-1-related receptor (SIGIRR),
and TNF-related apoptosis-inducing ligand receptor (TRAILR) and intracellular inhibitors, which can
inhibit TLR signaling at multiple levels. The intracellular inhibitors include sMyD88 (short isoform),
interleukin-1 receptor-associated kinase M (IRAK-M), suppressor of cytokine signaling 1 (SOCS1),
phosphatidylinositol 3-kinase (PI3-K), Toll interacting protein (Tollip), and A20. Negative regulators
ensure chronic inflammatory TLR responses to MAMPs (microbial associated molecular patterns) from
commensal bacteria do not occur. In fact, it is being discovered that many probiotics can modulate
TLR negative regulators in IECs to inhibit pathogen-induced inflammation and possibly contribute to
the tolerance of the intestinal barrier to commensal bacteria [44].
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Figure 2. Probiotic modulation of pathogen sensing by TLR-2 and TLR-4 signaling pathways.
Probiotic-mediated modulation of TLR-2 and TLR-4 signaling via direct and indirect mechanisms of
activation or suppression of distinct signaling molecules/pathways is strain-dependent. Mechanisms
of modulation are presented above for a range of strains of bifidobacteria (BL = B. longum strain
BB536; BB = B. breve strain M-16V), lactobacilli (LGG = L. rhamnosus strain GG; LC = L. casei strain
0LL2768; LJ = L. jensenii strain TL2937; LA = L. amylovorus strain DSM16698T), and the yeast
S. cerevisiae, indicated in the extracellular space above the intracellular post-membrane receptor
signaling pathways. TLR si nal transduction is initiated by TLR signal adaptor molecules, represented
by red ovals, which bind the TIR domains (orange box) on the TLR cytoplasmic region. Signal is
passed downstream via activation of IRAK-1 (purple box) and TRAF-6 (maroon box), resulting
in the activation of NFkB and MAPK pathways. Arrowed lines are activatory, blunted lines are
suppressive/inhibitory. Probiotic bacteria regulate inflammatory responses via induction of a range
of endogenous negative regulators of TLR signaling (IRAK-M, Tollip, A20, Ubcl2, Bcl-3 and p50/p50
NFkB homodimer). TLR2 ligation may induce a suppressive effect on TLR4-mediated inflammatory
responses via expression/activation of IRAK-M and Tollip. S. cerevisiae can exert a suppressive effect on
inflammatory responses via inhibition of MAPK pathways (p38, JNK and ERKs). At this time, studies
represented in this figure use a range of cells/cell lines; selective manipulation of signal checkpoint
molecules and pathways is likely to represent a cell and cell subset-specific nature.
Lactobacillus casei OLL2768 has been shown to attenuate the ETEC-induced pro-inflammatory
response by inhibiting NFκB and p38 MAPK signaling pathways in bovine intestinal epithelial (BIE)
cells, which reduced the expression of IL-6, IL-8, IL-1β and MCP-1 [28]. This was associated with the
negative regulation of TLR4 signaling via the up-regulation of Toll interacting protein (Tollip), which
inhibits the TLR adaptor protein, IRAK subsequently preventing the over-expression of NFκB and
therefore inflammatory damage. In addition, L. casei OLL2768 also up-regulated the nuclear protein,
B-cell lymphoma 3- encoded protein (Bcl-3). Bcl-3 is a member of the NFκB family, which is able to
stabilize repressive NFκB homodimers, for example p50/p50. The activation of Bcl-3 can therefore
prevent the binding of transcriptionally active dimers to gene promoters and effectively inhibit
pro-inflammatory responses. Another lactobacilli strain isolated from the intestines of unweaned pigs
has shown anti-inflammatory effects in human Caco-2/TC7 cells. L. amylovorus DSM 16698T protects
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IECs against the pro-inflammatory response triggered by ETEC K88 through the repression of the
pro-inflammatory cytokines IL-1β and IL-8 [27]. The protective activity of L. amylovorus DSM 16698T
was exerted by inhibiting various steps of TLR4 signaling via the modulation of negative regulators.
L. amylovorus inhibits the ETEC induced activation of TLR4 and MyD88, and the phosphorylation
of IKKα, IKKβ, IκBα and NFκB subunit p65, which subsequently inhibited the over-production
of inflammatory cytokines IL-8 and IL-1β. These anti-inflammatory effects are modulated by the
activation of the negative regulators of TLR4 signaling, Tollip and IRAK-M. Moreover, the use of
anti-TLR2 neutralising antibodies has helped clarify that the probiotic-dependent suppression of TLR4
signaling was dependent on TLR2. Other lactobacilli strains have also demonstrated anti-inflammatory
effects via the activation of negative regulation of TLR signaling. Lactobacillus jensenii TL2937
down-regulates TLR4-dependent NFκB and MAPK activation, consequently decreasing the expression
of pro-inflammatory cytokines and chemokines caused by ETEC or LPS challenge [32]. Furthermore,
this down-regulation was shown to be associated with the up-regulation of three negative regulators of
TLR4 signaling; A20, Bcl-3 and mitogen-activated protein kinase 1 (MKP)-1. A20 is an ubiquitin editing
protein, which inhibits activation of NFκB [45]. This protein functions to target proteins for proteasomal
degradation via the attachment of polyubiquitin chains to target proteins. Tumour necrosis factor
(TNF)-α-receptor-associated factor 6 (TRAF6) is a common target for A20 and therefore facilitates
the down-regulation of NFκB signaling in response to TLR activation [46]. In a similar study to
Shimazu et al. (2012) [32], the potential immunomodulatory effects of bifidobacteria strains were
investigated [25]. Bifidobacterium longum BB536 and B. breve M-16V strains were found to significantly
suppress IL-8, MCP-1 and IL-6 levels in porcine intestinal epithelial (PIE) cells in response to ETEC
PAMPs. These anti-inflammatory effects were shown to be associated with the modulation of NFκB and
MAPK pathways via the up-regulation of the ubiquitin-editing enzyme, A20. Moreover, the activity of
A20 was abolished when anti-TLR2 blocking antibodies were used. This suggests that bifidobacteria
may induce cross-tolerance in IECs through their interaction with TLR2 and the up-regulation of A20.
It may be that certain probiotics share a common mechanism for their immunomodulatory effects as it
has also been demonstrated that L. amylovorus activates the negative regulators of TLR4 signaling in a
TLR2-dependent manner. These studies demonstrate potential therapeutic strategies for the treatment
of intestinal inflammatory disorders in humans, induction of negative regulators of signaling cascades
may be crucial mechanisms whereby probiotics exert anti-inflammatory effects.
Modulation of pro-inflammatory cytokines: Epithelial barrier integrity can be affected by
pro-inflammatory cytokines, which are induced by activation of signaling pathways such as
NFκB and MAPK. Many studies have identified probiotic strains that suppress the production
of pro-inflammatory cytokines from IECs, via modulation of many checkpoints in these signaling
pathways, therefore reducing the detrimental inflammatory damage to the intestinal epithelial barrier
caused by pathogen-induced inflammation. Studies have shown that pretreatment of Caco-2BBe
(brush border-cytoskeletal model) cells with LGG decreased TNFα induced NFκB activation due to
inhibition of nuclear translocation of the NFκB subunit p65 [47] (refer to Figure 1). Subsequent gene
expression studies demonstrated that the chemokine CXCL-8 (IL-8, chemotactic for neutrophils)
and CCL-11 (Eotaxin, chemotactic for eosinophils) protein levels were decreased in LGG-treated,
cytokine-challenged cells. Moreover, LGG inoculation prevented TNFα-induced ZO-1 disruption.
These findings indicate that LGG alleviates the effects of pro-inflammatory cytokine induced
epithelial barrier disruption and further pro-inflammatory cytokine production through inhibition
of NFκB signaling. B. lactis has been shown to significantly suppress NFκB activation in human
HT-29 cells, when stimulated with the pro-inflammatory cytokines IL-1β and TNFα and LPS [26].
The down-regulation of activated NFκB correlated with the reduction of NFκB-binding activity
and suppression of IκB degradation. L. reuteri inhibits intestinal LPS-induced phospho-IκB activity
in newborn rats with necrotising enterocolitis (NEC) in ex vivo experiments [33]. This paralleled
down-regulation of mRNA expression of IL-6, TNFα, and IL-1β. Furthermore, intestinal protein levels
of TLR4 were also significantly reduced. This study demonstrates probiotic ability to down-regulate
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NFκB activity, which corresponds to reduced production of inflammatory mediators but can also
reduce the expression of TLR proteins hence regulate pathogen sensing.
Another way by which IκB degradation can be suppressed, is through increased amounts of
ROS. Studies have recently identified that probiotics modulate inflammatory responses by inducing
local generation of reactive oxygen species (ROS) [48]. ROS can regulate cellular processes through
oxidative inactivation of key regulatory enzymes. Specifically, LGG can induce ROS generation in
intestinal epithelia, which are able to exhibit increased oxidation of the Ubc12 enzyme [30]. Ubc12 is
responsible for the ubiquitination of the inhibitory molecule IκB, therefore IκBα is not targeted for
proteasomal degradation. Thus, NFκB remains bound to IκBα in the cytosol, unable to function
as a transcription factor and inducing gene expression. Furthermore, LGG was able to prevent
intraperitoneal TNFα-induced intestinal activation of NFκB in an ex vivo model of distal small
intestines isolated from immature C57BL/6J mice. This indicates that LGG reduces inflammatory
signaling by inducing ROS generation. Modulation of inflammatory signaling by production of
endogenous signals presents a mechanism for reducing pro-inflammatory responses to non-pathogenic
stimuli and may have implications for preventing inflammatory bowel diseases (IBD).
Recently, the commensal strain Streptococcus salivarius K12 was shown to suppress NFκB activation,
correlating with decreased IL-8 production [35]. The conditioned supernatant of S. salivarius inhibited
NFκB activity in HT-29 cells in response to TNFα, suggesting that the anti-inflammatory properties on
IECs are induced by an active metabolite from S. salivarius. Furthermore, this supernatant inhibited
NFκB activity induced by a variety of stimuli including IL-1β and the TLR5 ligand, flagellin. Therefore,
it was hypothesized that the inhibitory compound is localized downstream of the receptors which
is common to TNFα, IL-1β and flagellin receptors. This indicates that S. salivarius may be involved
in molecular cross-talk with a variety of receptors and may have potential for modulating the hosts
mucosal immune response in inflammatory disorders.
Probiotics can also affect MAPK signaling pathways to modulate cytokine production. Suppression of
expression of the pro-inflammatory cytokines IL-6 and IL-8 has been associated with the decreased
phosphorylation of ERK1/2 and p38. This was observed in IECs treated with Saccharomyces cerevisiae
(Sc). It was shown that IPEC-1 cells inhibited the ETEC-induced pro-inflammatory response when
pretreated with Sc [34]. This inhibition was associated with the decrease of ERK1/2 and p38 MAPK
phosphorylation, suggesting that Sc can inhibit ETEC-induced inflammation at the epithelial barrier.
Numerous studies have shown that certain strains of probiotics modulate the production
of pro-inflammatory cytokines. However, another way by which probiotics may exert
immunomodulatory effects is by stimulating the production of the anti-inflammatory cytokine IL-10.
In one such study, gene expression changes were observed in healthy 2-week old mouse colon samples
6 hours post oral ingestion of LGG. In vivo examination of gene expression changes demonstrated
that LGG down-regulated the expression of TNFα and MIP-2, but failed to alter IL-10. However,
LGG did induce mRNA expression of the IL-10R2 subunit of the IL-10 receptor [29]. IL-10 initiates
an anti-inflammatory response by binding to its receptor, which activates the JAK1/STAT3 pathway,
where STAT3 is phosphorylated [49]. Activated STAT3 inhibits the expression of pro-inflammatory
genes such as TNFα and MIP-2 and up-regulates the gene expression of members of the suppressor
of cytokine synthesis (SOCS) family. In the colons harvested from LGG-treated mice, there was
a significant increase in activated phospho-STAT3 and SOCS-3 expression, which correlated with
decreased expression of MIP-2 and TNFα. This study demonstrated the LGG anti-inflammatory effects
are mediated by STAT3 activation and downstream SOCS3 production and is most likely dependent
on induction of IL-10R2 expression and the consequent signaling through this receptor chain upon
ligation of the anti-inflammatory cytokine, IL-10.
2.3. Probiotic Modulation of IEC TLR Expression Regulates Mucosal Intestinal Immunity and Tolerance
IECs regulate translocation of luminal antigens and microorganisms into the lamina propria
and have been described to suppress DC activation and contribute to tolerance induction [50].
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DCs are present in the Peyer’s patches and recgonise antigens present in the lumen, which have
been transported to the Peyer’s patch via specialised IECs called microfold- or M cells [51]. DCs can
also protrude between IECs and sample antigens in the intestinal lumen [52]. Upon antigen recognition,
DCs transport the antigen within the patch or to the mesenteric lymph nodes where they are presented
to lymphocytes. It is probable that DCs can influence the outcome of T cell activation and induce
regulatory T cell populations that are essential for mucosal tolerance. Thus, PAMP/antigen capture
and recognition is fundamental to IEC/DC determination of immune activation or tolerisation.
Activation of apical TLR9 by probiotics: Under inflammatory conditions, IECs express increased
TLR2 and TLR4 on the apical surface, and this is associated with inflammatory bowel disease [53].
In contrast, apically-derived TLR9 stimulation has been described to be anti-inflammatory. It has been
shown that basolaterally-derived TLR9 activation in IECs, signals IκBα degradation and activation of
NFκB, whereas apically-derived TLR9 stimulation induces a potentially anti-inflammatory/regulatory
response in which ubiquitinated IκB accumulates in the cytoplasm preventing NFκB activation [54].
This suggests that apical but not basolateral TLR expression and activation in IECs can maintain
colonic homeostasis and regulate tolerance and inflammation.
TLR9 recognises unmethylated CpG motifs of bacterial DNA, which activates many downstream
signal pathways including NFκB. A study has demonstrated that living probiotics, probiotic DNA and
the synthetic oligodeoxynucleotides containing CpG motifs from LGG and B. longum BB536, increased
the levels of TLR9 mRNA and NFκB, as well as IκBα phosphorylation compared to a non-CpG control
group in an OVA-induced food hypersensitivity mouse model [55]. This correlated with skewing
towards a Th1 immune response, and increased percentage of CD4+CD25+ Treg cells (regulatory T
cells). This data suggests that activation of TLR9 by the combination of living probiotics or probiotic
DNA can prevent allergic responses by immune modulation. In line with this study, apical exposure of
polarized HT-29 to DNA from LGG was found to attenuate TNFα enhanced NFκB activity by reducing
IκBα degradation and p38 MAPK phosphorylation [56]. This anti-inflammatory effect of LGG was
indeed, mediated by TLR9 signaling; the silencing of TLR9 abolished the inhibitory effect of LGG.
A recent study has postulated that the capacity of a probiotic to stimulate immune responses
is species-specific and correlates with the frequency of motifs known to exert immunosuppressive
functions [57]. The study found that Lactobacillus paracasei DNA was enriched in suppressive sequences
and these correlated with the probiotic capacity to exert immunosuppressive functions in Lamina
propria DCs (LpDC). In particular, L paracasei DNA was able to inhibit DC activation and induce CD4+
Foxp3− Treg cells in a dose-dependent manner. These findings support the evidence that probiotics
exert their immunomodulatory effects by stimulation of TLR9, however these are species and dose
specific. Further, this suggests that a balance between regulatory and stimulatory motifs exists to
induce gut immune homeostasis, demonstrating that these regulatory motifs enriched in probiotics,
targeting TLR9, could be exploited for therapeutic purposes.
3. Probiotic Modulation of DCs
3.1. Activation of DCs
IECs are important in driving the development of tolerance by suppressing DC activation, which
subsequently controls the suppressive function of T regulatory cells (Tregs) [58]. IECs have also been
described to induce the development of CD103+ DC. This population of tolerogenic DCs induces
Foxp3+ Treg cells and is dependent on TGFβ and the dietary metabolite, retinoic acid (RA) [59], both
being produced by IECs. It is unknown whether TLR activation of IECs influences the generation
of tolerogenic DCs. However, it is clear that TLR stimulation in the intestinal epithelium plays an
important role in regulating mucosal immunity.
In one particular study, Bifidobacterium breve was shown to induce the development of
IL-10-producing Tr1 cells [60]. Intestinal CD103+ DCs mediated the induction of B. breve dependent
Tr1 cells. It was shown, using intestinal CD103+ DCs from MyD88 −/− and TLR −/− mice, that
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the tolerogenic DCs were activated via TLR2/MyD88-dependant production of IL-10 and the
Th2-inducing IL-12 family member cytokine, IL-27. These findings demonstrate that B. breve can
prevent intestinal inflammation through induction of IL-10-producing Tr1 cells, mediated through
TLR2/MyD88 signaling. Other studies have demonstrated the anti-inflammatory effects of probiotics
are CD103-dependent. However, these effects are not dependent on the same PRR and therefore
demonstrate that the anti-inflammatory effects are strain-specific. Lactobacillus salivarius Ls33 induced
the development of CD103+ DCs and CD4+ Foxp3+ regulatory T cells in an IL-10-dependent
manner [61]. Purification of PGN from Ls33 demonstrated that the protective effects of L. salivarius
were NOD2-dependent but MyD88-independent. Another study has identified a probiotic mixture,
IRT5 (Streptococcus thermophilus, L. reuteri, B. bifidium, L. acidophilus and L. casei), which up-regulates
the generation of CD4+Foxp3+ regulatory T cells (Tregs) from the CD4+CD25− population [62].
This conversion of T cells into Tregs is mediated by regulatory DCs, which express IL-10, TGFβ, COX-2
and tolerance-associated enzyme, indoleamine 2,3-dioxygenase (IDO), which regulates T cell function
through the depletion of tryptophan. Administration of this probiotic mixture had therapeutic effects
in experimental inflammatory bowel disease, which was associated with enrichment of CD4+Foxp3+
T regs in the inflamed regions and subsequently down-regulation of Th1, Th2, and Th17 cytokines
without apoptosis. These results represent an applicable treatment of inflammatory immune disorders,
which enhance the generation of regulatory DCs and Tregs (refer to Table 2).
The diversity of the gut microbiota influences the gut immune system and plays a major role
in inflammatory bowel diseases and allergies. These pathologies are highly stimulated by helper
T cell (Th) cell-skewing, induced by strong stimulatory bacteria in the gut microbiota. Lactobacilli
and bifidobacteria can have a positive effect on these inflammatory responses. Zeuthen et al. [63]
reported that beneficial effects of bifidobacteria are mediated by TLR2 recognition. The combination
of L. acidophilus X37, L. paracasei Z11, L. casei CRL431, LGG, B. longum Q46, B. bifidum Z9, B. breve
20091, and B. bifidum 20082a decreased IL-12 and TNFα and increased IL-10 levels, which inhibited
the Th1 skewing effect induced by strong immunostimulatory lactobacilli. It was shown that the
immunostimulatory effect of bifidobacteria is TLR2-dependent and NOD2-independent, suggesting
that bifidobacteria act as immunoregulators through interaction of lipoprotein with TLR2. Furthermore,
probiotics and their supernatants have immunomodulatory effects in human intestinal-like DCs,
mediated by cytokines and TLR recognition of MAMPs. Bifidobacterium breve CNCM-I-4035 and
its cell-free culture supernatant (CFS) have been shown to decrease pro-inflammatory cytokines
and chemokines in DC when challenged with Salmonella enterica serovar Typhi CECT725, which
was mediated by increased expression of TLR9 and TLR5 [64]. In contrast, the live strain B. breve
CNCM-I-4035 was a potent inducer of pro-inflammatory cytokines including TNFα, IL-8 (CXCL8,
recruitment of neutrophils, basophils and Tc) and RANTES (CCL5, recruitment of memory T cells,
monocytes, NK cells and immature DCs). Moreover, the CFS increased the expression of Caspase 8,
Tollip and IRAK4, whereas these genes were down-regulated by the live bacteria. This suggests that
the anti-inflammatory effects of the CFS may be mediated by inhibition of TLR signaling as Tollip is
an adaptor molecule which binds TLR2 and TLR4 to inhibit MyD88 binding and activation, therefore
inhibiting TLR signaling and subsequently pro-inflammatory cytokine production [65]. However, this
story is further complexed by the recognition that IRAK4 is able to bind and phosphorylate Tollip,
preventing its ability to interact with the TLR pathway. The supernatants of various other probiotic
strains have been investigated for their immunostimulatory effects. The CFS from Lactobacillus paracasei
CNCM I-4034 and Lactobacillus rhamnosus CNCM I-4036 decreased pro-inflammatory cytokines and
chemokines in human intestinal DCs challenged with Salmonella enterica serovar Typhi CECT725 and
Escherichia coli [66,67].
Finally, an ex vivo investigation, using murine bone marrow-derived DCs, has demonstrated
that there is a level of cross-regulation/cross-talk between species of probiotic bacteria, hence
fine-tuning immune signaling in DCs. Lactobacillus spp displayed differential induction of IL-12
and TNFα, whereas all strains tested augmented expression of the DC maturation markers, MHC II
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and CD86. When investigating two probiotic strains, L. reuteri DSM12246 (poor IL-12 inducer) and
L. casei CHCC3139 (high IL-12 inducer), it was observed that L. reuteri strain inhibited IL-12, IL-6
and TNFα induction and reduced CD86 up-regulation by the L. casei strain [68]. Thus, cross-talk
between probiotic species also has a role to play in defining the overall probiotic response as
immune-activatory/pro-inflammatory or immunosuppressive to DCs.
In summary, a specific probiotic bacterial strain could regulate gut homeostasis by facilitating
induction of Treg cells (refer to Table 2), inhibiting T cell-mediated mucosal inflammation, increasing
production of anti-inflammatory cytokines or decreasing pro-inflammatory cytokines, and mediating
TLR signaling. The combinations of different probiotics for treatment of IBD should be researched
further, as various combinations have shown promise in reducing inflammation in experimental
models. The use of CFS from specific probiotic strains may also prove successful for fine-tuning
immunomodulatory effects in vivo.
Table 2. Probiotic modulation of signaling pathways in intestinal dendritic cells.
Probiotic T Cell Activation PRR and Signaling Pathway Reference
Bifidobacterium breve
Yakult strain Tr1 cells TLR2/MyD88 [60]
B. longum BB536 DNA Increased CD4
+CD25+ Treg cells
& Th1 activation
TLR9 and IκB-α
phosphorylation [55]
IRT5 CD4+Foxp3+ regulatory T cells Not described. [62]
LGG DNA Increased CD4
+CD25+ Treg cells
and Th1 activation
TLR9 and IκB-α
phosphorylation [55]
LGG DNA ND
TLR9 and reduced IκBα
degradation and p38
phosphorylation
[56]
Lactobacillus paracasei
ATCC 25302 DNA CD4
+ Foxp3+ Treg cells TLR9 [57]
Lactobacillus salivarius
Ls33 CD4
+ Foxp3+ Treg cells NOD2 [61]
Probiotics differentially modulate dendritic cell responses via activation of distinct pathogen sensing signaling
pathways (TLR2, TLR9, NOD2) in a strain-dependent manner. Table also indicates the downstream effects on effector
T cells (Th1) and regulatory T cells (Treg). Observations presented include a range of strains of Bifidobacterium,
lactobacilli, and IRT5 probiotic mixture and the modulatory effect of probiotic DNA from L. rhamnosus GG and
B. longum BB536. ND, indicates not determined.
3.2. Probiotic Modulation of NK Cells via Cross-Talk with DCs
Natural killer cells (NKs) play a crucial role in the immune response to tumours and viruses.
NKs can distinguish between normal healthy cells and abnormal cells with altered or missing MHC
class I molecules [69]. Upon recognition of the abnormal cells, NKs can elicit the secretion of immune
mediators including IFNγ and TNFα or direct cytolysis of the infected or transformed cells. In addition,
NKs cells can be indirectly activated by secreted soluble factors from DCs such as IL-12, IL-18 and type
1 interferons (IFNα, IFNβ). The secretion of cytokines by DCs and indeed MΦs depends on the nature
of the stimuli received from microbial products. Recent studies have identified that LAB-induced DC
regulation may affect NK cell activity and subsequent anti-tumour or anti-viral immune responses.
NK cell activity has been shown to be enhanced by LAB in healthy adults. Administration of
Lactobacillus casei Shirota (LcS) to patients whose colonic polyps had been surgically removed significantly
reduced the recurrence of colorectal cancer. The specific mechanisms of action of LcS on NK cell
activity have also been explored. LcS induced IL-12 and TNFα production, which positively correlated
with NK activity [70]. Other studies have revealed that exposure of human DCs to LAB induces
activation, proliferation and cytotoxicity in NK cells and subsequent NK-derived IFNγ secretion [71].
This suggests that LAB modulate IFNγ production in NK cells in a DC-dependent manner. However,
not all probiotics have the same IFNγ-inducing capability. One study identified that only DCs matured
by L. acidophilus induced secretion of IFNγ from NK cells [71]. Combining L. acidophilus with a
non-inducing LAB completely abrogated DC-mediated IFNγ production by NK cells. The mechanisms
involved in DC-IL-12 production by L. acidophilus have still not been completely elucidated. However,
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this evidence suggests that combinatory probiotic therapy maybe counter-productive with respect
to NK-mediated immunity. In addition, the specific recognition of particular LABs by DCs and NK
cells are slowly being uncovered. It was found that oral intake of L. pentosus S-PT84 in C57BL/6
mice significantly enhanced NK activity, this increased activity correlated with activation of IL-12
production by CD11c+ DCs in a TLR2/TLR4-dependant manner [72].
The main action LABs have on NK cells is the enhancement of their cytotoxic activity and therefore
anti-tumour responses rather than the increase in NK cell count. In agreement with this, several human
studies have found that LcS supplementation enhanced NK cell activity where in vivo studies revealed
this to be due to IL-12 [73,74]. This evidence together suggests that some LAB efficiently initiate
NK/DC interactions, which subsequently increases the cytolytic potential of NK cells in mucosal
immunity. The potential of LAB strains to differentially induce IFNγ production by NK cells highlights
the ability to use these probiotics to modulate cytokine balance and to promote anti-tumour cytotoxic
immune responses. This demonstrates the potential to modulate immune dysregulation associated
with specific allergies and diseases where Th1 cell polarisation is the cause of the pro-inflammatory
reaction including the ability to stimulate anti-tumour responses.
With regards the signaling modulated by probiotic microbes, little direct evidence exists. What can
be proposed is that, due to NK cell reliance on activation by IL-12, IL-18, the relative balance between
KIR/KAR ligation and pathways specific to induction, expression and secretion of IFNγ, NK signaling
may be modulated by probiotic bacteria at many levels.
4. Probiotic Modulation of Neutrophils
Neutrophils are fundamental to innate immunity and recognition/responsiveness to pathogenic
challenge. They are short-lived myeloid cells that readily respond to infection via the
oxidative-dependent production of toxic reactive oxygen species (ROS), referred to as oxidative
burst, and by phagocytic clearance; both facilitated by neutrophil extracellular traps (NETs). Any such
effects of probiotic bacteria on neutrophils is likely to target its effector functions: ROS generation,
phagocytosis, NET formation, hydrolytic enzyme activity, chemokine-mediated recruitment and
inflammatory cytokine secretion; thus having a profound effect on neutrophil-mediated responses
associated with acute infection and chronic infection/immunopathology (refer to Table 3 below).
Table 3. Probiotic modulation of neutrophil effector function and signaling pathways.
Probiotic Effector Response Cells/Cell Line/Model Reference
L. gasseri NC1500
L. gasseri + MnSOD
NC1501
Reduction in severity of inflammation —decreased Nφ
& Mφ infiltration IL-10 deficient mouse model of colitis [75]
B. animalis
MB5L. rhamnosus GG
Probiotics & Secreted
factors
Inhibition of Nφ transmigration by suppression of
IL-8, Gro-α, ENAP-78 and suppression of chemokine
regulators, IL-1β & TNFα.
Enterotoxigenic E.coli K88 – induced
inflammation in Caco-2 epithelial cells [76]
B. lactis HN019 Increased Nφ phagocytic capacity & enhancedphagocyte-mediated bacteriocidal activity. Clinical trial: Healthy human PBMCs [77]
E. coli Nissle 1917 Amelioration of inflammation: Reduced levels of Nφs& chemokines.
DSS-induced colitis, murine model.
Prophylaxis – faecal transplantation model. [78]
L. rhamnosus NutRes1
B. breve NutRes204
Worsening of faecal condition accompanied by
reduced Nφ numbers. L. rhamnosus improved this &
increased TLR2/6, CCL2, TNFα, IL-1β, IL-6.
DSS-induced chronic colitis, murine model.
Relapse–Remision cycling. [79]
B. longum subsp. Infantis
BB-02
Reduction in inflammation: decreased Nφ infiltration
& CXCL-1. DSS-induced acute colitis, murine model. [80]
L. rhamnosus L34
L. casei L39
Suppression of IL-8 expression. Conditioned media:
L34 suppressed NFκB phosphorylation, L39
suppressed both NFκB & c-Jun.
C. difficile-associated disease colitis model.
Infant faecal isolates on HT-29 epithelial
cells.
[81]
L. gasseri ATC33323 cell
wall extract
Cell wall extract—lethality. Increased TNFα, IL-1β,
MIP-1α, MCP-1, NO & decreased Nφ count. Sepsis model in Sprague-Dawley rats. [82]
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Probiotic Effector Response Cells/Cell Line/Model Reference
L. rhamnosus Lcr35
AM development prevented by suppressing IL-4 (Th2),
IL-17 (Th17), TSLP via a Foxp3+ Treg-dependent
mechanism.
Murine OVA challenge allergic march (AM)
model. [83]
L. rhamnosus GG
Inhibition of PMA- and S.aureus-induced neutrophil
extracellular traps (NETs), ROS production &
phagocytic capacity.
HL60-derived Nφ cell model. [84]
B. longum OLL6001
Culture condensate
(BCC)
Augmentation of Nφ recruitment. Upregulation of
adhesion molecule & cytokine expression.
Immuno-enhancing.
Diet-restricted murine peritonitis model: ip
glycogen injection. [85]
VSL#3 Probiotic mixture Reduction in mucosal levels of Nφ chemoattractant,IL-8 & tissue influx of Nφs.
Human retrospective study of proB-treated
UC pouchitis. [86]
L. plantarum ATCC10241 Reduction in bacterial load, Nφ numbers,apoptotic/necrotic cells and IL-8. Wound healing.
Chronic infected leg ulcers (diabetic and
non-diabetic). [87]
Clostridium butyricum
MIYAIRI 588
Anti-tumour effects by MMP-8 driven release of
TRAIL (TLR2/4–dependent)
Nφs in BCG-responsive bladder cancer
patients [88]
Probiotics differentially modulate neutrophil effector responses via activation of distinct pathogen sensing signaling
pathways in a strain-dependent manner. Observations presented include a range of LAB strains of bifidobacteria,
lactobacilli, and Escherichia coli Nissle 1917. Effector responses to probiotic introduction are indicated as modulation
of phagocytosis, killing activity, inflammation and cytokine production, which by inference are linked to effects on
pathogen sensing and signaling pathways. These observations have been recorded for a range of neutrophil studies
using distinct primary cells, cell lines and in vivo models indicated.
To date, little is known how probiotic bacteria influence signaling pathways involved in neutrophil
effector functionality. What is known is by inference of modulation of effector molecules, which
are typically regulated by established signal pathways. B. animalis MB5 and L. rhamnosus GG
strains have been shown to suppress enterotoxigenic E. coli K88 induction of the NFκB-dependent
inflammatory mediators TNFα, IL-1β, IL-8, Gro-α and ENAP-78 [76], resulting in a corresponding
inhibition of neutrophil transmigration. In contrast however, L. rhamnosus NutRes1 increased the distal
colon expression of CCL2, TNFα, IL-1β, IL-6 and the pathogen-sensing receptors, TLR2/6 whereas
neutrophil numbers (Ly-6B.2+) and activity (MPO) were reduced in a murine DSS-induced chronic
colitis model [79]. L. rhamnosus GG has also been shown to inhibit NET formation and as a consequence,
reduced ROS production and prevention of tissue destruction through chronic inflammation [84];
the suppression of ROS production being suggestive of an inhibitory effect on NFκB. Additionally,
the cell-wall extract of L. gasseri ATC33323 upregulated the expression of TNFα, IL-1β, MIP-1α and
MCP-1 in a Sprague-Dawley rat model of sepsis [82], whereas conditioned medium from L. rhamnosus
L34 and L. casei L39 differentially regulated NFκB and c-Jun activation in a C. difficile-induced colitis
model: L34 suppressed NFκB and L39 suppressed both NFκB and c-Jun involved in IL-8 production,
hence neutrophil activation and recruitment [81]. Finally, granulopoeisis or the de novo generation of
neutrophils is dependent on G-CSF, which induces the expression of neutrophil-specific genes in a
STAT3/STAT5-dependent manner, negatively regulated upon the expression of SOCS3. Observations
that specific LABs induce G-CSF, STAT3 activation and SOCS3 are suggestive of a distinct role for
probiotics in controlling neutrophil numbers and activity through a cytokine receptor-JAK/STAT-SOCS
axis [89–91] and (reviewed in [92]). Thus, probiotic modulation of neutrophil signaling is in its infancy
and can be summarised to both positively and negatively regulate NFκB, JAK-STATs and JNK MAPK
signaling in a manner that is determined by probiotic strain, probiotic format (whole bacteria, cell-wall
extract or secreted molecules), PRRs utilised and context of neutrophil/tissue model (homeostatic or
pathological) being investigated.
5. Probiotic Modulation of Macrophage Signaling Pathways Influences Cytokine Production
Probiotics modulate various signaling pathways within macrophages and have subsequent
immunoregulatory functions on mucosal immunity. Extensive research has focused on the modulation
of cytokine production by probiotics. In addition to the innate pro-inflammatory cytokines such as
TNFα, IL-1β, IL-6 and IL-8, particular attention has been focussed on IL-10 and IL-12, as the production
of these cytokines by macrophages and other immune cells in response to microbes can determine the
type of immune response downstream of innate sensing. As in IECs, various signaling pathways are the
target of probiotic modulation, including NFκB and ERK1/2, p38 and JNK MAPKs. The mechanisms
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by which the production of cytokine secretion is modulated by probiotics are beginning to be uncovered
(refer to Table 4).
5.1. Modulation of Pro-Inflammatory Cytokines
Probiotics can suppress inflammation by inhibiting various signaling pathway checkpoints.
These signaling pathways include NFκB pathway, which may also be associated with changes in
MAPK pathways and PRRs (refer to Table 4). Various probiotics can inhibit IκBα phosphorylation
or ubiquitination and the subsequent degradation of this NFκB inhibitor [93], and decrease p65
nuclear translocation resulting in reduced NFκB DNA binding [94]. Select probiotics can also
inhibit LPS binding to the CD14 receptor, resulting in an overall reduction in NFκB activation
and therefore pro-inflammatory cytokine production [95]. Some of these probiotics can also inhibit
MAPK pathway checkpoints, indicating that both NFκB and MAPKs play a role in pro-inflammatory
cytokine production and that the use of probiotics, targeting these pathways may have a profound
anti-inflammatory effect. For example, LTA (lipoteichoic acid, a TLR2 ligand) isolated from Lactobacillus
plantarum (pLTA) inhibited the LPS-induced (TLR4-specific) TNFα production by decreasing the
degradation of IκBα and IκBβ resulting in suppression of NFκB activation [96]. Additionally, pLTA
pretreatment inhibited the phosphorylation of ERK, JNK and p38 MAPKs in THP-1 monocytic cells,
which is suggestive of signaling pathways modulated by endotoxin tolerisation (ET). Upstream of
the NFκB and MAPK pathways is the recognition of microbes by PRRs, and these components are
also affected by pLTA. The LPS-induced expression of TLR4, NOD1 and NOD2 is suppressed by
pLTA, along with the induction of IRAK-M, which acts as a negative regulator of TLR signaling [96].
This suggests that pLTA induces tolerance to LPS (ET), since these PRRs are involved in LPS recognition.
However, expression of the LPS co-receptor, CD14, was increased in pLTA tolerised cells, suggesting
that CD14 also participates in the interaction between TLR2 and LTA, which may result in decreased
interaction between CD14 and LPS, therefore reducing inflammation (refer to Table 4). These results
suggest that pLTA may be effective in the prevention and treatment of LPS-induced septic shock.
Furthermore, purified pLTA inhibits S. aureus LTA (aLTA)-induced TNFα production in THP-1 cells,
thus exhibiting a level of TLR2-mediated homo-tolerisation [97]. The effects of pLTA on NOD signaling
have also been further investigated. The pro-inflammatory response induced by Shigella flexneri
PGN (flexPGN) on THP-1 cells was reduced, upon pretreatment with pLTA: resulting in a significant
reduction in TNFα and IL-1β production, which was associated with down-regulation of NOD2
expression, suggesting that pLTA can modulate flexPGN-induced inflammation [98]. Furthermore,
pLTA–tolerant THP-1 cells had reduced phosphorylation of ERK, JNK and p38 MAPKs as well as
decreased NFκB activity. These results indicated that pLTA could induce cross-tolerance between
TLR2 and NOD2 signaling against a NOD2 agonist such as flexPGN (refer to Figure 2). (For further
information on probiotic modulation on ET, refer to Section 5.6).
In addition to modulation of the NFκB pathways, probiotics can inhibit the transcription factor
AP-1 (heterodimer of fos/jun) via inhibition of the MAPK-regulated c-Jun. A specific strain of L. reuteri,
ATCC PTA 6475, suppressed TNFα transcription by inhibiting activation of c-Jun and subsequently
AP-1 [99] (refer to Figure 2). The levels of pro-inflammatory cytokines can also be modulated by
activation of suppressor of cytokine signaling (SOCS) family proteins. SOCS proteins are negative
regulators of cytokine signaling pathways mediated by JAK-dependent activation/phosphorylation
of dimeric STAT transcription factors; the combination of JAK/STAT/SOCS isoforms determining
immune gene expression profiles, hence macrophage functionality (reviewed in [92]). In general,
STAT1 is associated with IFNγ and IL-12 signaling whereas STAT3 is associated with anti-inflammatory
signaling of IL-10 and IL-6. SOCS3 is inducible by IL-10 and IL-6 and can serve to both suppress
pro-inflammatory cytokine gene expression as well as negatively feeding back to inhibit IL-10 and
IL-6 signaling. Bifidobacterium species decreased LPS-induced IL-1 and TNFα mRNA levels in murine
RAW264.7 macrophage cells [100], which correlated with inhibition of IκB phosphorylation and
increased mRNA levels of SOCS1 and SOCS3. A similar study also demonstrated B. breve, LGG
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and L. helveticus to induce macrophage SOCS3 expression [91]. Together, these studies demonstrate
that different inflammatory pathways can be modulated by different probiotics in order to induce
anti-inflammatory effects. Such anti-inflammatory effects are not exclusively restricted to the direct
effect of probiotic-dependent SOCS-suppression of inflammatory cytokines in macrophage cells; LABs
inducing the expression of SOCS2 (L. plantarum) and SOCS3 (L. acidophilus), have been demonstrated
to both activate/phosphorylate STAT-1 and STAT-3 whereas inactivating JAK2 and hence, downstream
TNFα and IL-8 secretion [90]. Such effects on JAK2 would have profound and discriminatory effects
on macrophage polarization and subset-specific responses where JAK2 is essential for GM-CSF and
IFNγ signaling but not for IL-6 and IFNα/β signaling (refer to M1 and M2 macrophage subsets later
in Section 5.1).
In addition to IL-10, G-CSF has been shown to have anti-inflammatory effects. L. rhamnosus
strains GG and GR-1 have been shown to elicit the release of G-CSF from macrophages and that G-CSF
has a paracrine effect on neighboring macrophages and can suppress inflammatory responses [89].
G-CSF suppresses TNFα production, mediated by the activation of STAT3 and subsequently c-Jun
inhibition. Furthermore, strain GR-1 treatment increased G-CSF production in normal human
intestinal lamina propria cells. Reduced G-CSF production however, was observed in cells isolated
from IBD patient tissue [101]. G-CSF-mediated mechanisms of action are being elucidated; using
G-CSFR- deficient DCs, it was observed that GR-1-conditioned media induced significant IL-12/23 p40
production, which indicated that the G-CSF within the GR-1 conditioned media inhibited IL-12/23 p40
production [102]. This suggests that GR-1 can regulate immune responses through releasing G-CSF,
and that G-CSF inhibits pro-inflammatory cytokine production via crosstalk between macrophages
and dendritic cells. Altogether, these results suggest that production of G-CSF induced by L. rhamnosus
may have anti-inflammatory effects on key immune cells in the intestine and may be important in
maintaining normal immunological homeostasis in the intestine.
Table 4. Probiotic modulation of signaling pathways in macrophage cells.
Probiotic Effector Response Cells/Cell Line Reference
L. casei Shirota
L. fermentum MS15
L. PlantarumNCIMB41605
L. salivarius NCIMB41606
B. breve NCIMB 8807
TNFα: Increased—CD14hi M1/M2
Decreased—CD14lo M1/M2
IL-6: Decreased—M2
NF-κB: Decreased—M1
Increased—M2
M1 & M2 Mφ subsets (THP-1
cell line)
[103]
[104]
Secreted Protein +/− IL-6 M1 Mφs+/− IL-8/TNFα M1 & M2 Mφ subsets (THP-1)
[103]
[104]
SCFA-butyrate Suppression of IL-12 & augmentation of IL-10 Human monocytes [105]
SCFA-butyrate Decreased TNFαIncreased IL-10
M1 & M2 Mφ
subsets (THP-1) [106]
L. helveticus DSM13137
L. rhamnosus GG
S. thermophilus THS
B. breve DSM13692
Increased IL-10:IL-12 ratios
Induced SOCS3 (IL-10 & p38
MAPK-dependent)
Human Mφs
GM-CSF-PB monocytes [91]
L. plantarum K8
KCTC10887BP LTA
(pLTA)
Suppression of LPS
Induced TNFα (pLTA suppn of ERK, JNK, p38
MAPK
phosphorylation, IκB degradation & TLR4.
Induction of IRAK-M.
THP-1 & U937 pro-monocytes
Murine sepsis model L929-BMM
Balb/c
[96]
L. plantarum
KCTC10887BP LTA
(pLTA)
Suppression of S. aureus LTA (aLTA) induced
TNFα
pLTA suppresses Myd88, NFκB & MAPKs.
Antagonises aLTA.
THP-1 pro-monocytes [97]
L. plantarum
KCTC10887BP LTA
(pLTA)
Suppression of S. flexneri PGN
Induced inflammation (TNFα, IL-1β). Toln
decreases NOD2; pLTA cross Toln Flex PGN
THP-1 pro-monocytes [98]
B. breve ATCC15700
B. longum ATCC15697
Enterococcus faecalis
ATCC19433
Differential modulation of TNFα, IL-1β,
IL-12p40 mRNA. Decreased IκB
phosphorylation and induction of SOCS-1, -3.
RAW264.7 murine Mφs
LPS-stimulated [100]
LAB LTA
L. plantarum
ATCC14917T L. casei
YIT9029
Regulate TLR2-dependent
ERK mediated IL-12/IL-10 axis: LP high
IL-10/IL-12, LC low IL-10/IL-12.
Murine peritoneal Mφs Balb/c [107]
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Table 4. Cont.
Probiotic Effector Response Cells/Cell Line Reference
L. rhamnosus GR1 & GG G-CSF-mediated inhibition of JNK:Suppression of TNFα
Murine immort peritoneal &
BMM C57Bl/6 Human THP-1s [89]
ProB DNA L. casei &
B. breve Induction of IL-1, IL-10 & IL-6 Human PBMCs [108]
L. paracasei Cultech TLR2-dependent up-regulation of negativeregulators of NFκB
Human PBMCs & PMA-THP-1
cells. [109]
L. reuteri ATCC PTA 6475
CF48-3A & ATCC55730
conditioned medium
Suppression of LPS-induced TNFα & MCP-1
via inhibition of MAPK-driven cJun/AP-1actn
THP-1 cells, MonoMac-6 cells,
CD Mφs [99]
Probiotics differentially modulate macrophage responses via activation of distinct pathogen sensing signaling
pathways in a strain-dependent manner. Observations presented include a range of strains of bifidobacteria,
lactobacilli, and streptococci and enterococci and the modulatory effect of probiotic DNA, conditioned medium,
cell wall lipoteichoic acid (LTA) and the short-chain fatty acid (SCFA) metabolite, butyrate. Effector responses
to probiotic introduction (and their products) are indicated as modulation of inflammation, pathogen sensing,
cytokine production and their linkage to effects on signaling molecules and pathways. These observations have been
recorded for a range of macrophage studies using distinct primary cells, cell lines and ex vivo models indicated.
Although characterisation of probiotic modulation of MΦ signaling pathways is progressing at
a high speed, what is being overlooked however, is the differential effects of probiotics on distinct
MΦ subsets. In general, MΦs exist in two canonical subsets; M1 MΦs, which are pro-inflammatory
and anti-inflammatory/regulatory M2 MΦs. M2 MΦs are associated with mucosal homeostasis
and tolerance, mediated by anti-inflammatory/regulatory cytokines that they produce, including
IL-10, TGFβ and IL-1Ra. M1 MΦs, on the other hand, are associated with immune activation and
pro-inflammatory responses driven by TNFα, IL-1β, IL-6, IL-8 and IL-12, produced by this subset
(reviewed in [110]). The desired effect would be to utilise probiotics to selectively regulate MΦ subsets,
whereby M1 MΦs are inhibited in inflammatory pathologies and M2 MΦs inhibited in suppressive
pathologies such as mucosal cancers [111]. To this end, a panel of probiotic strains including L. casei
Shirota, L. fermentum, L. plantarum, L. salivarius and B. breve have been described to selectively modulate
LPS-induced M1 and M2 MΦ production of TNFα, IL-6 and the activation of NFκB; all of which were
also dependent on the expression of the TLR2/TLR4-associated co-receptor, CD14 [103,104] (refer to
Table 4). The potential of probiotic bacteria to regulate the pro-inflammatory M1 MΦ subset via effects
on TNFα secretion and the fact that cytokines often exhibit a level of redundancy have necessitated
further investigation to the control of signaling events and secretion of pro-inflammatory cytokines
with overlapping functionality to TNFα. Two such cytokines related to each other and exhibiting this
functional redundancy to TNFα are IL-1β and IL-18; both of which produced as pro-cytokines and
require distinct processing pathways prior to secretion.
5.2. Inflammasomes
As a consequence of modulating the expression and secretion of the pro-inflammatory cytokine,
IL-1β, probiotics have recently been suggested to play an active role in regulating the expression,
assembly and activity of the inflammasome, involved in the caspase-1-dependent processing of both
IL-1β and a related pro-inflammatory cytokine, IL-18. The inflammasome is not just involved in
processing IL-1β and IL-18 but is also associated with anti-viral responses, through the induction
of type I interferons and pyroptosis (inflammatory cell death that exhibits some characteristics of
apoptosis) (Reviewed in [112]). This variety of response associated with inflammasome activity is
determined by a range of sensor proteins, which associate to form distinct inflammasome subtypes.
These inflammasome subtype protein complexes are defined by these sensor proteins, namely NLRP1,
NLRP3, NLRP6, NLRC4 (IPAF) and AIM2; each having distinct protein binding partners and sensing
either a selective or broad range of activating stimuli. An early investigation has indicated this
complexity in inflammasome activity, where two strains of L. rhamnosus (LGG and LC705), have been
described to process and secrete IL-1β in macrophages. In contrast however, was the differential effect
on anti-viral responses; strain LC705 induced the activation of type I interferons whereas LGG did
not. This is suggestive of probiotic strain-dependent expression, assembly and activity of distinct
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inflammasome subtypes in macrophage cells. Thus, probiotic strains may be used to selectively
regulate inflammatory responses and anti-viral defences by selectively modulating IL-1β, IL-18 and
type I IFNs respectively, through the signaling assembly and activity of distinct inflammasomes.
The NLRP1 inflammasome can be found in monocytes, macrophages, DCs, granulocytes as well
as T cells and B cells [113]; this inflammasome can be activated by MDP which results in caspase-1
activation [114] and the further interaction of NOD2 with NLRP1 is desirable for pro-IL-1β expression
in an NFκB-independent manner [115]. Further complexity is added to this signaling process by
the observation that type I IFNs inhibit NLRP3-mediated caspase-1 activation in a STAT-1-mediated
process [116]; such a process may be indicative of a macrophage subset-specific signaling process.
STAT1 has been shown to be associated with the pro-inflammatory M1 MΦ subset whereas M2 MΦs
utilize STAT3 and STAT6 [110]. This differential utilization of STATs, coupled with responsiveness to
cytokines has an impact on the type of inflammasome activated, hence downstream effector functions.
As such, the effect of probiotic bacteria on inflammasome isoform, activation and IL-1β/IL-18-mediated
functionality can potentially offer an attractive regimen for control of immune cell signaling and
warrants extensive investigation.
5.3. Modulation of the IL-12/IL-10 Balance
The cytokine response by macrophages varies between different strains of probiotics. Lactobacilli
DNA has been identified as a strong inducer of IL-12 production, whereas, bifidobacteria genomic
DNA can induce the secretion of the anti-inflammatory cytokine, interleukin-10 [108,117] (refer to
Table 4). The mechanisms by which lactobacilli strains differentially induce IL-12 and IL-10 production
have been investigated. L. plantarum potently induces IL-10 but weakly induces IL-12 production,
whereas L. casei potently induces IL-12 but weakly induces IL-10 production. It was shown that
L. plantarum induction of IL-10 was dependent on activation of MAPK pathways, especially ERK;
selective blockade of ERK activation resulted in reduced IL-10 production [107]. The key factor for
triggering IL-10 production was identified as bacterial teichoic acids, mediated by TLR2-dependent
ERK activation. Furthermore, the IL-12-inducing strain, L. casei, can be converted into a potent IL-10
inducer in the presence of these teichoic acids. This differential cytokine response was shown to be
due to the resistance to intracellular digestion characteristic of lactobacilli strains with a rigid cell wall,
such as L. casei. Easily digestible lactobacilli, such as L. plantarm, or their intact cell walls (ICWs) only
weakly induce IL-12 production in macrophages and, furthermore, act as bacteria regulators, inhibiting
L. casei-induced IL-12 production. However, the ICW of L. casei did not inhibit L. casei-induced IL-12
production, but its peptidoglycan was sensitive to intracellular digestion and inhibited L. casei-induced
IL-12 production. This suggests that the suppression of IL-12 by particular lactobacilli is dependent
on NOD2, the receptor for the PGN breakdown product, MDP [118]. These studies reveal novel
mechanisms for the negative regulation of IL-12 production, whereby easily digestible lactobacilli
strains counteract the strong immunostimulatory effects of other lactobacilli strains via NOD2
stimulation and TLR2-dependent ERK activation. This observation demonstrates that selective
recognition of specific bacterial components are responsible for the immunoregulatory functions of
different probiotic strains and provides theoretical basis for the understanding of their multifunctional
activities and thus will contribute to more effective utilization and selection of probiotics in health
maintenance and disease prevention.
5.4. Lipid Rafts—CD14, TLR2 and TLR4
It is now quite evident that probiotics have the capability to modulate innate immune
responsiveness. This modulation may occur by directly suppressing or activating signal transduction
molecules, induction of the expression of endogenous negative regulatory molecules, regulation of
expression of receptors and their co-receptors or via the induction of exogenous regulatory molecules
such as IL-10. One mechanism that is important to innate pattern sensing is the way by which
receptors and co-receptors are introduced to form receptor complexes capable of transmitting the
Nutrients 2017, 9, 1156 19 of 31
reception event. This process depends on the fluidity of the cell membrane and the bringing together
of receptor proteins on lipid rafts. Integral to this rafting of related receptor protein complexes
is the activity of LysoPC:acyl-CoA acyltransferase-2 (LPCAT2). This enzyme is involved in LPS
responses of macrophages and allows for the assembly of CD14 with the LPS receptor, TLR4 as well
as the LTA receptor, TLR2 [119]. The activity of LPCAT is up-regulated upon macrophage priming,
rendering these cells hyper-responsive to LPS (reviewed in [120]). These priming responses can be
driven by the pro-inflammatory cytokines, TNFα and IFNγ [121,122], thus membrane phosphatidyl
choline (PC) composition and its effect on membrane fluidity is likely to affect lipid rafting and the
association of LPS-sensing receptors and co-receptors [123,124]. Probiotic bacteria have already been
implicated in controlling TLR4 expression and TLR4-mediated signaling; it is likely that probiotics
may be in future, be implicated in controlling LPCAT2 activity hence phospholipid composition
either directly or indirectly through pro-inflammatory priming cytokines such as TNFα and IFNγ.
Probiotic modulation of LPCAT2 activity and phospholipid-mediated membrane fluidity potentially
offers a way of discriminating between innate immune activation and suppression.
5.5. Regulation by miRNA
Micro-RNAs (miRs) are small, non-coding RNAs of approximately 20 nucleotides in length, that
regulate cellular responses by binding to target mRNAs and promoting post-translational control of
mRNA expression via transcript degradation or inhibition of translation. In general, miRs play
an important role in the regulation of inflammation and immune responses through activation
or the suppression of innate immunity, through the induction of endotoxin tolerisation (ET). One
widely studied micro-RNA, miR-155, has been demonstrated to be a key pro-inflammatory regulator.
As such, miR-155 targets known regulators of inflammation including PU.1, SHIP1, SMAD5 and
SOCS1 [125]. Genome knock-out of miR-155 in RAW264.7 murine macrophages, up-regulated SHIP1
whereas impaired LPS-induced pro-inflammatory cytokine production (TNFα, IL-6, IL-12) [126,127].
This association of miR-155 with inflammatory response led to a similar investigation, whereby
miR-155 was demonstrated to play an important role in macrophage polarisation towards the
pro-inflammatory M1 macrophage subset, mediated by LPS and IFNγ. Knock-out of this micro-RNA
resulted in the selective suppression of IL-1β and TNFα with no effect on the M2-associated marker
enzyme, Arg-1 [128]. Thus, manipulation of miRNAs represents a potential mechanism to selectively
regulate inflammatory processes either directly, via modulation of cytokine expression, or indirectly
via manipulation of macrophage polarisation and endotoxin tolerisation (ET) mechanisms through
negative regulators of PRR signaling. Recent studies have shown miRNA-146a to be up-regulated
through TLR2 and further up-regulated upon ET protocols. This TLR2-dependent miRNA-146a
induction was shown to suppress TNFα production through a reduction in IRAK-1 expression and IκBα
phosphorylation [129]. Given the LTA-TLR2 dependency of certain probiotic modulating mechanisms,
the relative expression of miR-146a to miR-155 may represent a future molecular switch, manipulating
inflammation versus suppression. In addition, feeding of piglets with Enterococcus faecium NCIMB
10415 up-regulated miRNA-423-5p in the small intestine, which was associated with a positive
homeostatic effect on immunoglobulin expression, facilitating mucosal barrier functionality [130].
Future studies will further clarify the role of probiotic bacteria in controlling innate cell signaling
through the modulation of miRNA expression.
5.6. Probiotics as Vehicles of Endotoxin Tolerisation
Probiotic bacteria can be both Gram positive and Gram negative and exhibit a wide range
of MAMPs/PAMPs, shared with pathogenic organisms and recognised by PRRs. Thus, probiotic
bacteria may initiate responses through a combination of MAMPs; including LTA (TLR2), PGN
(NOD-1/NOD-2), DNA (TLR9), Flagellin (TLR5) and LPS (TLR4). The subtleties behind discriminating
between initiation of immune inflammatory responses and suppression/regulation of immune
responses requires extensive investigation (refer to Figure 3). Such understanding will allow the
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true harnessing of probiotic and commensal organisms in prophylaxis and direct treatment of a
diverse range of immunopathologies. Probiotics are essentially live vehicles for delivery of a variety of
MAMPs: simultaneous recognition, staggered or delayed recognition of which will have a profound
effect on immune responses. Indeed, staggered recognition of single or multiple different MAMPs
is fundamental to hyporesponsiveness in homo- and hetero-tolerisation in innate immune system
[reviewed in [131,132].
Understanding the role played by probiotics in driving endotoxin tolerisation (ET) will allow
specific and selective utilisation of probiotic bacteria in the treatment of many pathological conditions.
The mechanisms by which these organisms tolerise innate immune signaling is diverse. Such mechanisms
harnessed in ET have been partially described earlier; these include (1) antagonism of PAMP binding;
(2) Down-regulation of PRR expression; (3) Induction of suppressive cytokines e.g., IL-10 [91,105–108];
(4) Activation of antagonistic pathways e.g., PI3K; (5) Induction of miRNAs [129,130]; (6) Expression
of engogenous suppressors of TLR signalling e.g., A20, Tollip, IRAK-M, TRIAD3A and p50/p50
NFκB [91,96,100,109]; (7) Expression and reception events of suppressive receptors e.g., SIGIRR,
FcγRIIb (CD32) and Siglecs 3-10 and (8) Cross-regulation of TLR signaling e.g., NOD2 regulation of
TLR2, TLR9 regulation of TLR2/4, TLR7/8 regulation of TLR4 ([98] and reviewed in [131]).Nutrients 2017, 9, 1156  22 of 33 
 
 
Figure  3.  Immune  stimulation  or  tolerisation?—Probiotics  hold  the  key!  Probiotics  differentially 
modulate  macrophage  responses  via  activation  and  suppression  of  distinct  pathogen  sensing 
signaling  pathways  in  a  strain‐dependent manner.  Both  pathogenic  (red)  and  probiotic  (green) 
bacteria  can  express  similar/overlapping  profiles  of  PAMPs/MAMPs  (LTA,  LPS,  Flagellin,  PGN, 
DNA)  through a  range of PRRs  including external‐facing TLR2  (homodimeric or heterodimerised 
with TLR1 or TLR6), TLR4, TLR5, and intracellular NOD1, NOD2 and endosomal TLR9. All of which 
can transduce  immune activatory/inflammatory responses through activation of NFkB and MAPK 
signal pathways (indicated in red arrows). In addition, secondary exposure and chronic exposure to 
probiotic‐derived MAMPs (indicated in green arrows), induce a suppressive/tolerogenic response via 
the  induction  of  endogenous  negative  regulators  to  TLR  signals  (Tollip,  IRAK‐M, Myd88s, A20, 
TRIAD3A and miRNAs) that inhibit NFkB and MAPK pathways. Finally, recognition of PGN and its 
breakdown products through NODs‐1 and ‐2 (indicated in a blue arrow) can have both a positive and 
negative effect on  the  inflammatory  response  that may be determined by  selective NOD  receptor 
utilisation or specific structural differences between PAMPs and MAMPs. TIR domain and TLR signal 
adaptor molecules are indicated in the blue key box. 
Both  pathogenic  and  commensal/probiotic  bacteria  share  common  patterns, which  activate 
innate inflammatory signal mechanisms and drive the production of innate activatory cytokines and 
exogenous signaling molecules. The differential responsiveness to pathogens and probiotics is likely 
to  be  determined  by  subtleties  in  PAMP/MAMP  structure  and  the  relative  strength  of  negative 
regulatory/tolerisation  molecule  network.  Understanding  single,  multiple,  simultaneous  or 
staggered  PRR  reception  events  will  clearly  unravel  the  complexities  of  innate  cell  activation, 
differentiation, polarization  and  tolerisation  through probiotic MAMP‐PRR  signaling, which will 
facilitate  the  scientific  understanding  and  potential  use  of  probiotics  and  their  products  in  the 
regulation of immune‐activatory and suppressive pathologies.   
Figure 3. Immune stimulation or tolerisation?—Probiotics hold the key! Probiotics differentially
modulate macrophage responses vi activatio and suppression of distinct pathogen sensing signaling
pathways in a strain-dependent manner. Both pathogenic (red) and probiotic (green) bacteria can
express similar/overlapping profiles of PAMPs/MAMPs (LTA, LPS, Flagellin, PGN, DNA) through a
range of PRRs inclu ing extern l-facing TLR2 (homodimeric or eterodimerised with TLR1 or TLR6),
TLR4, TLR5, and intracellular NOD1, NOD2 and endosomal TLR9. All of which can transduce immune
activatory/inflammatory responses through activation of NFkB and MAPK signal pathways (indicated
in red arrows). In addition, secondary exposure and chronic exposu e to probiotic-derived MAMPs
(indicated in green arrows), induce a suppressive/tolerogenic response via the induction of endogenous
negative regulators to TLR signals (Tollip, IRAK-M, Myd88s, A20, TRIAD3A and miRNAs) that inhibit
NFkB and MAPK pathways. Fi ally, recognition of PGN and its breakdown products through NODs-1
and -2 (indicated in a blue arrow) can have both a positive and negative effect on the inflammatory
response that may be determined by selective NOD receptor utilisation or specific structural differences
between PAMPs and MAMPs. TIR domain and TLR signal adaptor molecules are indicated in the blue
key box.
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Both pathogenic and commensal/probiotic bacteria share common patterns, which activate
innate inflammatory signal mechanisms and drive the production of innate activatory cytokines
and exogenous signaling molecules. The differential responsiveness to pathogens and probiotics
is likely to be determined by subtleties in PAMP/MAMP structure and the relative strength of
negative regulatory/tolerisation molecule network. Understanding single, multiple, simultaneous
or staggered PRR reception events will clearly unravel the complexities of innate cell activation,
differentiation, polarization and tolerisation through probiotic MAMP-PRR signaling, which will
facilitate the scientific understanding and potential use of probiotics and their products in the regulation
of immune-activatory and suppressive pathologies.
6. Secreted Proteins, Lipids, Polysaccharides and Metabolites
With the vast proliferation of investigations that have described immunomodulatory capability of
probiotic bacteria is the realisation that the whole organism may not be required, even be replaced
by proteins, lipids, polysaccharides and metabolites that are secreted by these bacteria. As such,
there are many observations characterising secreted products as immune-modulating and backed
up by description of their mechanistic effects on immune cell signaling. There is a vast array
of secreted molecules, either fully described or simply as secreted proteins/polysaccharides or
conditioned media (refer to Table 5). As early as 2000, extracellular phosphopolysaccharide from
L. delbrueckii ssp. bulgaricus was described to have an immune-enhancing effect on macrophage
phagocytosis [133]; although its effect on signaling molecules was not fully appreciated, this study
was suggestive of a mechanism which cleared pathogen/cellular debris, hence modulating destructive
inflammatory processes.
Several studies have focussed on the effects of secreted products in probiotic conditioned medium.
Purified proteins from LGG conditioned media (p75 and p40) have been shown to activate PKB/Akt
involved in the suppression of TNFα-mediated epithelial cell damage [134]. Conditioned media from
L. plantarum (Lp-CM) inhibited TNFα-induced MCP-1 secretion by epithelial cells and macrophages
via inhibition of NFκB and proteasome activity [135]. Supernatant from culture of L. fermentum
inhibits Y. enterocolitica-induced epithelial cell IL-8 by suppressing Rac, p38 MAPK and NFκB activity.
This suppressive activity being abrogated by phospholipase C, indicating the suppressive activity to be
mediated by a secreted phospholipid [136]. In addition, L. rhamnosus L34 and L. casei L39 conditioned
media suppress C. difficile-induced colonic epithelial cell IL-8 and GM-CSF production: L34 suppressed
NFκB whereas L39 suppressed both NFκB and c-jun phosphorylation [81]. Thus, conditioned media
from probiotic bacterial species has been demonstrated to either activate (PKB/Akt) or suppress (Rac,
MAPKs, NFκB) a variety of signaling pathways that is both strain-dependent and dependent on the
nature of the secreted products (proteins and lipids). Early mass-spectrometry data is suggestive
that L. rhamnosus GG secretes Serpin β1 and a transcriptional regulator [137]. Employment of further
proteomic and lipidomic approaches will reinforce our understanding of secreted products capable of
modulating innate immune signaling.
Table 5. Probiotic-derived MAMPs, secreted products and metabolites modulate immune
signaling pathways.
Probiotic Format Effector Response Cells/Cell Line Reference
L. fermentum MS15
L. plantarum
NCIMB41605 L. salivarius
NCIMB41606 B. breve
NCIMB8807 Secreted
Protein
TNFα: Increased—CD14hi M1
Selective suppression—CD14loM1/M2
IL-6: Decreased—M2
NFκB: Selective suppression—CD14hiM1.
Increased—M2
M1 & M2 Mφ subsets
(THP-1 cell line) [103]
L. casei Shirota
Secreted
Protein
Suppressed LPS-induced TNFα, NFκB
activation & augmented IL-1β (M1 Mφs).
Suppressed LPS-induced IL-6 & augmented
IL-1β (M2 Mφs), independent of NFκB
activation.
M1 & M2 Mφ subsets
(THP-1 cell line) [104]
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Table 5. Cont.
Probiotic Format Effector Response Cells/Cell Line Reference
SCFA-butyrate
Suppression of LPS/PGN-induced TNFα (M1
& M2). Suppression of LPS/PGN-induced
IL-1β (M2). Augmentation of
LPS/PGN-induced IL-10 (M2). Suppression of
monocyte LPS/PGN—induced TNFα & IL-1β.
M1 & M2 Mφ subsets
(THP-1 cell line) [106]
L. plantarum
(Non-designated strain)
Conditioned medium
(Lp-CM)
Inhibition of NFκB binding activity
andproteosome-dependent degredation of
IκBα. (Stimuli: TNFα, LPS, Flagellin, Poly I:C).
Suppression of MCP-1 secretion.
Murine YAMC intestinal
epithelial cells, RAW264.7 Mφs,
Primary DCs
[135]
L. plantarum K8
KCTC10887BP LTA
(pLTA)
Suppression of LPS-induced TNFα pLTA
suppn of ERK, JNK, p38 MAPK
phosphorylation, IκB degradation & TLR4.
Induction of IRAK-M expression.
THP-1 & U937 pro-monocytes.
Murine sepsis model L929-BMM
Balb/c
[96]
L. plantarum
KCTC10887BP LTA
(pLTA)
Suppression of S. aureus LTA (aLTA) induced
TNFα
pLTA suppresses Myd88, NFκB & MAPKs.
Antagonises aLTA.
THP-1 pro-monocytes [97]
L. plantarum
KCTC10887BP LTA
(pLTA)
Suppression of S. flexneri PGN
induced inflammation (TNFα, IL-1β). Toln
decreases NOD2; pLTA cross Toln Flex PGN
THP-1 pro-monocytes [98]
L. rhamnosus GG p75 &
p40 secreted proteins
Protection from H2O2-mediated damage to IEC
barrier TJs (PKC & MAPK-dependent). IECs
[134]
[138]
LAB LTA
L. plantarum
ATCC14917T
L. casei YIT9029
Regulate TLR2-dependent
ERK mediated IL-12/IL-10 axis: LP high
IL-10/IL-12, LC low IL-10/IL-12.
Murine peritoneal Mφs Balb/c [107]
L. rhamnosus GG secreted
protein Serpin B1,
protease inhibitor of
neutrophil elastase. Band
G2 & G4.
Prevention of epithelial cell barrier damage. Mass Spec. (MS/MS) analysis ofLGG S/N grown in MRS broth. [137]
ProB DNA
L. casei & B. breve Induction of IL-1, IL-10 & IL-6 Human PBMCs [108]
L. rhamnosus GG DNA Immunostimulation Murine immune cells B cells [117]
Bifidobacteria
(Non-designated strain)
unmethylated CpG DNA
Augmentation of Mφ phagocytosis, NO release
and secretion of IL-1β, IL-6, IL-12p40 and
TNFα (CpG DNA recognised by TLR9).
Murine Mφs : J774A.1 cells [139]
Probiotic-derived products differentially modulate immune cell effector responses via activation of distinct pathogen
sensing signaling pathways. Observations presented include the modulatory effect of probiotic DNA, conditioned
medium, cell wall lipoteichoic acid (LTA) and the short-chain fatty acid (SCFA) metabolite, butyrate for a range
of strains of bifidobacteria and lactobacilli. Effector responses to introduction of probiotic-derived products are
indicated as modulation of inflammation, pathogen sensing, cytokine production and their linkage to effects on
signaling molecules and pathways. These observations have been recorded for a range of studies using distinct
primary cells, cell lines and ex vivo models indicated.
As a result of gastrointestinal processing of probiotic bacteria, products, such as DNA and cell
wall components, released upon breakdown of probiotics may also have a profound effect on innate
signaling. Indeed, DNA from bifidobacteria has been described to activate macrophage expression of
NO, IL-1β, IL-6, IL-12p40 and TNFα), thus driving an activatory/pro-inflammatory response [108,139].
In comparison, purified cell wall from L. gasseri also stimulates an inflammatory response, inducing the
expression and secretion of IL-1β, TNFα, MIP-1α, MCP-1, IL-10 and NO [82]. Whereas pLTA derived
from the cell wall of L. plantarum antagonises and cross-tolerises LTA and PGN-induced inflammatory
responses via suppression of NFκB and MAPK signaling pathways [96–98].
Finally, anaerobic metabolic breakdown of complex carbohydrates can result in the production of
products such as the short chain fatty acids, butyrate, proprionate and acetate. Indeed, butyrate, which
can also act as a histone deacetylase inhibitor, has been shown to inhibit pro-inflammatory cytokine
expression in both monocytes and macrophages while simultaneously inducing the expression of
the anti-inflammatory cytokine, IL-10 [105]. This has been suggested via a mechanism involving the
inhibition of NFκB activation [140]; this is not the case however, in the study using THP-1-derived
macrophages [105], where it is possible that the inhibitory effect on pro-inflammatory cytokines may
be downstream, and secondary to a positive regulation of IL-10 or indeed to butyrate modulation of
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NOD2 responsiveness to PGN [141]. Manipulation of responsiveness to butyrate and expression of
receptors to SCFAs offer another mechanism for control of inflammatory mechanisms.
7. Conclusions
Probiotics have been used to treat a range of health conditions encompassing intestinal and
extraintestinal sites, including atopic dermatitis, necrotising enterocolitis, pouchitis and ulcerative
colitis [142–144]. The mechanisms for the observed health effects of these probiotics are not fully
understood, but are likely due to the direct/indirect action on the intestinal immune system.
As summarized in this review, probiotics have been documented to modulate key immune responses
within the gut by modulating signaling pathways including NFκB, MAPK, PI3K/Akt and JAK/STAT
signaling. The actions of these probiotics are seen within IECs, DC, neutrophils and macrophages,
however the probiotic mechanisms of action are often strain-specific and can have varied responses
within different host cells. If the use of probiotics is to continue, it will be of crucial importance to
identify the precise probiotic responses and relevant effector molecules, along with the effected host
cell signaling events. This will allow us to explore the effects of different strains on host immune
responses and elucidate currently unknown probiotic modulation of signaling events within host cells.
Future directions should continue to study gene expression to explore how bacteria affect
intestinal biology and to elucidate cellular populations within the intestinal microbiota to identify
how these contribute to changes in intestinal physiology. This review has identified the diversity
of effector functions produced by different strains of the same bacterial species. In combination
with functional and comparative gene-based approaches, a greater understanding of strain-specific
effector functions and the ways in which such strains modulate signaling events, will enable
selection of the most appropriate probiotic strain or possible genetically-engineered probiotic to
treat gastrointestinal diseases.
There are many areas of probiotic-immunomodulation, that require extensive investigation,
one of which is the role of probiotics in modulation of APC function, in particular macrophages.
These APCs are able to regulate local immune responses by activating or suppressing inflammatory
pathologies. In particular, mucosal macrophages have been characterised into effector subsets, M1
(pro-inflammatory) and M2 (anti-inflammatory/regulatory). Manipulation of macrophage plasticity by
probiotics through regulation of effector functions via manipulation of intracellular signaling pathways
may hold potential for macrophage-based therapies to treat mucosal inflammatory pathologies.
Given that certain probiotics have already shown to be a successful regime for particular
health conditions, future development should therefore focus on underpinning the specific signaling
mechanisms of immunopathologies within the gut and how they may be specifically, and selectively
modulated by probiotics. As indicated in this review, probiotics can exert modulatory effects on signal
pathways involved in immune activation, deviation or regulation/suppression, therefore probiotic
strain selection or probiotic combination should be carefully considered, in the context of immune cell
signaling, in order to achieve the desired immunomodulatory effect.
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